CD44 and neoplasm: Importantly, in tumor, mHAdLyp.sT treatment also increased the percentage of CD8+ central memory cells (TCM, CD44+CD62L+) significantly on day 14 (Fig. 4C, the right panel, P < 0.05 vs buffer).